Baird analyst Catherine Ramsey Schulte raised the firm’s price target on Natera to $117 from $99 and keeps an Outperform rating on the shares. The firm said they reported 1Q results well ahead of their model, even excluding one-timers, with ~41% revenue growth ex-true-ups, robust gross margin expansion, and positive cash flow for the first time.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA:
- Baird says FDA final LDT rule favorable for Life Sciences, Diagnostics coverage
- TipRanks’ ‘Perfect 10’ List: Analysts See Opportunity in These 2 Top-Scoring Stocks
- Natera announces publication of dd-cfDNA study data
- Natera assumed with a Buy at Craig-Hallum
- Natera announces new data from two studies on Prospera Heart dd-cfDNA test
